Zurcher Kantonalbank Zurich Cantonalbank Has $141,000 Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in ImmunityBio, Inc. (NASDAQ:IBRX) by 46.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 28,105 shares of the company’s stock after purchasing an additional 8,932 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in ImmunityBio were worth $141,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Wealth Effects LLC grew its position in ImmunityBio by 11.2% in the fourth quarter. Wealth Effects LLC now owns 59,500 shares of the company’s stock valued at $299,000 after acquiring an additional 6,000 shares during the last quarter. Aire Advisors LLC acquired a new stake in shares of ImmunityBio in the 3rd quarter valued at approximately $25,000. Courier Capital LLC bought a new stake in shares of ImmunityBio during the 4th quarter valued at approximately $75,000. SG Americas Securities LLC increased its position in ImmunityBio by 45.4% during the 4th quarter. SG Americas Securities LLC now owns 49,005 shares of the company’s stock worth $246,000 after purchasing an additional 15,308 shares in the last quarter. Finally, WINTON GROUP Ltd bought a new position in ImmunityBio in the 3rd quarter valued at approximately $26,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler upped their price target on shares of ImmunityBio from $5.00 to $6.00 and gave the stock a “neutral” rating in a report on Monday, April 29th.

ImmunityBio Trading Down 4.1 %

ImmunityBio stock opened at $7.92 on Thursday. The company has a market capitalization of $5.36 billion, a PE ratio of -6.83 and a beta of 1.16. The stock has a 50-day moving average price of $5.81 and a two-hundred day moving average price of $4.58. ImmunityBio, Inc. has a 12 month low of $1.25 and a 12 month high of $10.53.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Tuesday, March 19th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.03 million. As a group, analysts predict that ImmunityBio, Inc. will post -0.76 earnings per share for the current fiscal year.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.